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Cerebral differences between
dopamine-resistant and dopamine-responsive
Parkinson’s tremor
Michiel F. Dirkx,1,2 Heidemarie Zach,1,2,3 Annelies van Nuland,1 Bastiaan R. Bloem,2
Ivan Toni1 and Rick C. Helmich1,2
Rest tremor in Parkinson’s disease is related to cerebral activity in both the basal ganglia and a cerebello-thalamo-cortical circuit.
Clinically, there is strong interindividual variation in the therapeutic response of tremor to dopaminergic medication. This obser-
vation casts doubt on the idea that Parkinson’s tremor has a dopaminergic basis. An interesting alternative explanation is that
interindividual differences in the pathophysiology of tremor may underlie this clinical heterogeneity. Previous work showed that
dopaminergic medication reduces Parkinson’s tremor by inhibiting tremulous activity in the pallidum and thalamus, and this may
explain why some tremors are dopamine-responsive. Here we test the hypothesis that dopamine-resistant resting tremor may be
explained by increased contributions of non-dopaminergic brain regions, such as the cerebellum. To test this hypothesis, we first
performed a levodopa challenge test in 83 tremulous Parkinson’s disease patients, and selected 20 patients with a markedly
dopamine-responsive tremor (71% reduction) and 14 patients with a markedly dopamine-resistant tremor (6% reduction). The
dopamine response of other core motor symptoms was matched between groups. Next, in all 34 patients, we used combined EMG-
functional MRI to quantify tremor-related brain activity during two separate sessions (crossover, double-blind, counterbalanced
design): after placebo, or after 200/50mg dispersible levodopa/benserazide. We compared tremor-related brain activity between
groups and medication sessions. Both groups showed tremor amplitude-related brain activity in a cerebello-thalamo-cortical circuit.
Dopamine-resistant tremor patients showed increased tremor-related activity in non-dopaminergic areas (cerebellum), whereas the
dopamine-responsive group showed increased tremor-related activity in the thalamus and secondary somatosensory cortex (across
medication sessions). Levodopa inhibited tremor-related thalamic responses in both groups, but this effect was significantly greater in
dopamine-responsive patients. These results suggest that dopamine-resistant tremor may be explained by increased cerebellar and
reduced somatosensory influences onto the cerebellar thalamus, making this region less susceptible to the inhibitory effects of dopamine.
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Introduction
Parkinson’s disease is a progressive neurodegenerative
disorder characterized among others by nigrostriatal dopa-
mine depletion (Kish et al., 1988). However, while dopa-
minergic medication effectively treats bradykinesia and
rigidity, the effect on resting tremor is unpredictable and
varies greatly between patients (Koller, 1986; Koller and
Hubble, 1990). The cerebral mechanisms underlying this
variable treatment response are unknown, limiting the de-
velopment of alternative treatment strategies for dopamine-
resistant tremor. In previous work we identified a cerebral
tremor network in Parkinson’s disease consisting of both
the basal ganglia and a cerebello-thalamo-cortical motor
circuit (Helmich et al., 2011; Dirkx et al., 2016).
According to the ‘dimmer-switch hypothesis’, the basal
ganglia initiate tremor-related activity, which is then pro-
pagated to the cerebello-thalamo-cortical circuit via the
motor cortex (Dirkx et al., 2016). In turn, the cerebello-
thalamo-cortical circuit maintains and amplifies tremulous
activity, which may occur via afferent signals that stabilize
intrinsic tremor oscillations (Volkmann et al., 1996;
Helmich, 2018).
Recent observations provide a number of possibilities that
may explain between-patient variations in the clinical dopa-
mine response of resting tremor. First, we recently found that a
dopaminergic intervention influences tremor-related activity
in the basal ganglia (pallidum) and the cerebellar receiving
nucleus of the thalamus (ventrolateral posterior nucleus,
pars ventralis, VLpv) (Dirkx et al., 2017). Clinical dopamine
responsiveness correlated with dopamine-induced inhibition
of tremor activity in the VLpv, suggesting that dopamine-re-
sistant tremormay be due to failure of dopamine to inhibit the
VLpv. Second, patients with Parkinson’s disease have exten-
sive Lewy body pathology in the cerebellum, with links to the
occurrence of (dopamine-resistant) tremor (Seidel et al.,
2017). Furthermore, it is clear from other (non-dopaminergic)
tremor diseases, for example essential tremor (Muthuraman
et al., 2018), that cerebellar pathology can drive tremu-
lous activity within the cerebello-thalamo-cortical circuit
(Hopfner and Helmich, 2018). This suggests that dopamine-
resistant tremor may be due to increased tremor-related activ-
ity in non-dopaminergic brain regions, particularly the
cerebellum.
To test these possibilities, we carefully selected
Parkinson’s disease patients with either a dopamine-resist-
ant or a dopamine-responsive tremor from a large cohort
(n = 83) that underwent a clinical levodopa challenge, prior
to functional MRI. Subsequently, we performed concurrent
functional MRI and electromyography (EMG) on two sep-
arate sessions: OFF dopaminergic medication (placebo) and
ON (levodopa) dopaminergic medication (standardized
challenge of 200/50mg levodopa/benserazide). We used
these data to compare tremor-related brain activity between
Parkinson’s disease patients with a dopamine-resistant
versus a dopamine-responsive tremor.
Materials and methods
Study population and design
We included 83 patients diagnosed with idiopathic Parkinson’s
disease (according to the UK Brain Bank criteria), with resting
tremor of at least one arm, and a history of resting tremor.
Exclusion criteria were: (i) neurological co-morbidity; (ii) signs
of psychogenic tremor (e.g. entrainment or distractibility); (iii)
known allergy against levodopa-benserazide or domperidone;
and (iv) significant cognitive impairment [Mini-Mental State
Examination (MMSE) (Folstein et al., 1975) score 524 or
frontal assessment battery (FAB) (Dubois et al., 2000) 512].
The study was approved by the local ethics committee and
written informed consent was collected before inclusion.
In all patients, we carried out a levodopa challenge test to
select those patients showing a clear dopamine-responsive or
dopamine-resistant tremor (Fig. 1A). Patients came to our
clinic in the morning after overnight fasting, in a practically
defined OFF state (i.e. 412 h after their last dose of levodopa,
430 h after their last dose of dopaminergic agonists and
424 h after their last dose of beta-blockers) (Albanese et al.,
2001; Zach et al., 2017) and after abstention from caffeine
(tea, coffee) for at least 12 h. None of the included patients
used beta-blockers to treat tremor; they were prescribed for
hypertension or cardiac disease. Using clinical rating scales
(Movement Disorders Society-Unified Parkinson’s Disease
Rating Scale; MDS-UPDRS) and accelerometry, patients were
measured both before and after levodopa. For the ON state
(levodopa) assessment, patients received a standard dose of
200/50mg dispersible levodopa-benserazide (this was on aver-
age 75% higher than the patients’ own morning dose) 1 h after
20mg domperidone. There is currently no consensus on the
definition of tremor dopamine responsiveness. This is why we
used (arbitrary) predefined criteria, which we validated after
data collection using an automated, data-driven clustering ap-
proach (supplementary analyses). We predefined dopamine-re-
sistant tremor as a clinical improvement of 420% on the
MDS-UPDRS rest tremor score (item 17), and dopamine-re-
sponsive tremor as a clinical improvement of 560%
(Albanese et al., 2001). Furthermore, only patients who
showed 520% improvement of rigidity and bradykinesia
(determined using items 3–8 of the MDS-UPDRS) were
included (Albanese et al., 2001), to rule out trivial explan-
ations for levodopa resistance, such as gastro-intestinal malab-
sorption (Nonnekes et al., 2016). These criteria were registered
at the Dutch Trial Registry prior to onset of the study
(www.trialregister.nl; trial number NTR5042), although we
later had to change the criterion for dopamine-responsive
tremor from 560% to 550% to reach our target of 20 dopa-
mine-responsive patients. All measurements took place from
July 2014 until February 2016.
After inclusion, we compared limb rigidity (MDS-UPDRS
item 3), limb bradykinesia (MDS-UPDRS items 4–8) and
limb resting tremor (MDS-UPDRS item 17) between both
groups using a 2  2 ANOVA with factors Group (dopa-
mine-resistant versus responsive) and Medication (placebo
versus dopamine) with post hoc one and two sample t-tests
in SPSS (two-tailed) (Fig. 1 and Table 1). To objectively quan-
tify tremor, we used a bi-axial piezoelectric accelerometer
(Medifactory International; sampling frequency 128Hz)
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attached to the affected upper extremity during the levodopa
challenge test. Using FieldTrip (Oostenveld et al., 2011), we
calculated the mean tremor power values (log transformed)
across three 1-min trials both at rest and during cognitive
stress (i.e. counting backwards from 100 in steps of 7 as fast
as possible), and during both OFF and ON (for details see
Zach et al., 2017) (Table 1).
Patients with a dopamine-resistant (n = 19) or dopamine-re-
sponsive tremor (n = 21) were scanned using functional MRI
on two separate days (Fig. 1A). Patients came to our clinic in a
practically defined OFF state. They received 20mg of domper-
idone and either 200/50mg dispersible levodopa-benserazide
or a placebo (dispersible cellulose) in a crossover, counterba-
lanced design. There were no significant time differences be-
tween intake of substance and scanning in both groups and
sessions [dopamine-resistant: placebo 52  6min, levodopa
53  19min; dopamine responsive: placebo 48  10min,
levodopa 48  9min (mean  standard deviation);
Medication  Group: F(1,32) = 0.053, P = 0.82]. Before and
after scanning patients were evaluated clinically using the
MDS-UPDRS by an experienced movement disorders specialist
who was blinded to group assignment and the intervention.
After scanning, we only included patients who had a clear
resting tremor in (at least) the placebo state based on the
EMG power spectrum measured during actual scanning. This
resulted in 20 patients with a dopamine-responsive tremor and
14 patients with a dopamine-resistant tremor.
Image acquisition and preprocessing
Functional MRI was carried out on a 3T MRI system
(Siemens PRISMA). Patients were instructed to lie still with
eyes open, which we confirmed with online eye-tracking. We
used a multi-band echo planar imaging sequence (multi-band
Figure 1 Study design and clinical results. (A) Study design and selection of patients. (B–D) Comparison of clinical dopaminergic response
in each of the three cardinal symptoms in each group. It can be seen that only limb resting tremor improved following levodopa in the dopamine-
responsive group (orange bars) but not in the dopamine-resistant group (blue bars). The bar graphs show the mean (  SEM) and all individual
datapoints. There were no outliers (defined as lower/greater than mean  three times the standard deviation). Note that there was one
dopamine-responsive patient who did not have a tremor during clinical evaluation in the placebo session, but who showed a clear peak in the
power spectrum (frequency range) of the EMG/accelerometry signal during scanning, indicating that this patient did have a tremor during the
functional MRI (fMRI) measurement. PD = Parkinson’s disease.
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acceleration factor = 4; repetition time = 0.859 s; echo
time = 34ms; 44 axial slices; voxel size = 2.2mm isotropic;
field of view = 225mm; scanning time 10min; 700 images).
The first five images were discarded. High resolution anatom-
ical images were acquired using a magnetization-prepared
rapid gradient-echo sequence (repetition time = 2.300 s; echo
time = 3.03ms; voxel size = 1.0mm isotropic; 192 sagittal
slices, field of view = 256mm; scanning time5 min).
Functional MRI images were analysed using SPM12 (http://
www.fil.ion.ucl.ac.uk) and FEAT (FMRI Expert Analysis Tool)
Version 6.00, part of FSL (FMRIB’s Software Library, www.
fmrib.ox.ac.uk/fsl). First, we used ICA-AROMA (independent
component analysis-based automatic removal of motion arte-
facts) to remove noise components in an automated, observer-
independent manner (Pruim et al., 2015). As ICA-AROMA is
scripted in FSL, we performed several preprocessing steps in
FSL: image registration, motion correction, non-brain removal,
spatial smoothing (using a Gaussian kernel of 5mm full-width
at half-maximum) and grand-mean intensity normalization
(Jenkinson and Smith, 2001). All components were visually
checked. Next, output images from ICA-AROMA (realigned
and in native space) were further preprocessed in SPM12: (i)
co-registered to structural MRI image; (ii) normalized to MNI
(Montreal Neurological Institute) space; and (iii) spatially
smoothed using a 6mm Gaussian kernel (resulting in a net
smoothing kernel of 7.8mm). Structural images were seg-
mented and normalized using a unified segmentation approach
(Ashburner and Friston, 2005).
Table 1 Clinical characteristics prior to scanning
Characteristic Resistant tremor (n = 14) Responsive tremor (n = 20) Two-sample t-test /
Fisher’s exact test
Age 61.2 (4.3) 65.3 (2.1) N.S.
Gender (male/female) 11/3 9/11 0.08
Disease duration (years) 2.3 (1.9) 5.2 (5.5) N.S.
Hoehn and Yahr 2 (1–3) 2 (2–3) N.S.
FAB 17.6 (0.5) 17.0 (1.1) N.S.
MMSE 29.4 (0.8) 29.1 (1.5) N.S.
LEDD 346.9 (207.5) 529.0 (63.9) 0.04
Levodopa usage 86% 95% N.S.
Dopamine agonist usage 21% 30% N.S.
Beta-blocker usage 28% 10% N.S.
Levodopa challenge test
(prior to scanning)
Resistant tremor (n = 14) Responsive tremor (n = 20) ANOVA (repeated
measures)
OFF L-DOPA OFF L-DOPA
MDS-UPDRS
Total 40.0 (18.5) 28.1 (14.7) 46.5 (14.2) 21.4 (10.6) F(1,32) = 35.7; P5 0.001
Limb bradykinesia 13.8 (7.6) 8.1 (5.7) 17.1 (6.0) 9.5 (5.4) N.S.
Limb bigidity 4.2 (3.6) 2.3 (2.7) 5.3 (2.6) 2.3 (2.0) N.S.
Limb resting tremor
MA-UE 3.1 (0.7) 2.9 (0.7) 2.8 (0.7) 1.5 (1.1) F(1,32) = 22.2; P5 0.001
MA-LE 1.4 (1.0) 1.4 (1.0) 1.7 (1.0) 0.1 (0.2) F(1,32) = 40.2; P5 0.001
LA-UE 1.3 (1.3) 1.3 (1.3) 1.3 (1.2) 0.5 (1.1) F(1,32) = 15.2; P5 0.001
LA-LE 0.8 (0.8) 1.6 (0.7) 1 (1.0) 0.2 (0.5) F(1,32) = 7.2; P = 0.01
Lip 0.4 (0.6) 0.2 (0.4) 0.4 (0.6) 0.1 (0.2) N.S.
Constancy 3.9 (0.3) 3.6 (0.6) 3.4 (1.0) 0.9 (0.5) F(1,32) = 46.2; P5 0.001
Limb postural tremor
MA 1.7 (0.7) 1.2 2.3 (1.1) 0.7 (0.7) F(1,32) = 10.2; P = 0.003
LA 0.9 (0.9) 0.9 0.9 (1.1) 0.3 (0.6) F(1,32) = 4.3; P = 0.045
Limb kinetic tremor
MA 1.1 (0.8) 0.9 1.0 (0.9) 0.5 (0.6) N.S.
LA 0.8 (0.7) 0.6 0.7 (0.7) 0.2 (0.4) N.S.
Accelerometer tremor [log(power)]
Rest (mean of 3  1 min) 6.6 (3.0) 5.1 (3.0) 5.3 (3.2) 0.04 (1.6) F(1,32) = 12.2; P = 0.001
Cognitive stress (mean of 3  1 min) 9.7 (3.1) 8.9 (2.9) 7.8(3.4) 2.5 (2.2) F(1,32) = 19.9; P5 0.001
Disease characteristics of all patients included for the functional MRI study are shown (Hoehn and Yahr: median, minimum and maximum scores in parentheses; other parameters:
mean, standard deviation in parentheses). Disease severity of each patient was measured using the Hoehn and Yahr stages (maximum = 5) and the MDS-UPDRS part III (maximum
score = 132). Limb rigidity was calculated as the sum of MDS-UPDRS item 3 (excluding item ‘Neck’; min–max score 0–16), limb bradykinesia as the sum of items 4–8 (min–max score
0–40). All tremor (sub)items of the UPDRS are displayed (items 15–17; min–max score 0–4 per sub-item). Tremor is also objectified during the levodopa challenge test using
accelerometer recordings of the most affected upper extremity. Accelerometer power values are log transformed and averaged across three trials of 1 min in rest and during
cognitive stress (counting backwards from 100 to 7 as fast as possible). Group comparisons were carried out using two-sample t-tests (two-tailed) and a repeated measures ANOVA
for quantitative variables and Fisher’s exact test for categorical variables. FAB = Frontal Assessment Battery; LA = least affected; LE = lower extremity; LEDD = levodopa equivalent
daily dose; MA = most affected; MMSE = Mini-Mental State Examination; N.S. = not significant.; UE = upper extremity.
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Tremor-related EMG activity
We used the same procedures as previously (Dirkx et al.,
2016, 2017). During MRI scanning, we measured activity of
the most affected forearm muscles (extensor digitorum com-
munis and flexor carpi radialis muscles) using MRI-compat-
ible EMG (Brain Products; sampling frequency = 5000 Hz).
Preprocessing included (i) removal of MRI-induced artefacts
(van der Meer et al., 2010); and (ii) high-pass filtering 42Hz
to remove slow frequency drifts and rectification to capture the
frequency of muscle bursts (using FieldTrip). Subsequently,
we used FieldTrip to calculate time-frequency representations
between 2–8 Hz in steps of 0.001 s using a 2 s Hanning taper,
resulting in a 0.5Hz spectral resolution. For each patient,
we calculated the time course of the EMG at each subject’s
individual tremor frequency  1.5 Hz [dopamine-resistant;
placebo: 4.2  0.2Hz, levodopa: 4.2  0.1Hz; dopamine re-
sponsive; placebo: 4.9  0.2Hz, levodopa: 4.8  0.2Hz,
mean  standard error of the mean (SEM)];
Medication  Group: [F(1,32) = 0.64, P = 0.43]. This resulted
in patient-specific regressors describing fluctuations in tremor
amplitude (EMG-amp). To remove outliers, data were loga-
rithmically transformed and z-normalized within subjects. The
first temporal derivative of the EMG-amp regressor was cal-
culated to account for changes in tremor amplitude (EMG-
change).
Tremor-related brain activity
In SPM12, we carried out a multiple regression analysis at the
first level for each subject using a general linear model (GLM)
including two regressors of interest (EMG-amp and EMG-
change after haemodynamic convolution) and two regressors
of no interest (average signal across the whole brain and bi-
lateral ventricles to correct for non-neural noise) (Power et al.,
2014). Parameter estimates for all regressors were obtained by
maximum likelihood estimation.
First-level contrast images showing tremor-related activity
(i.e. EMG-amp and EMG-change per session and averaged
across sessions) as well as dopaminergic effects on tremor-
related activity (EMG-amp and EMG-change in placebo
versus levodopa) entered a second-level analysis (random ef-
fects). We used a one-sample t-test to test for effects across all
34 patients. To test for differences between patients with a
dopamine-responsive versus dopamine-resistant tremor, we
used a 2  2 full-factorial design with factors Group (be-
tween-subject) and Medication (within-subject). Specifically,
we looked for main effects of group, medication and an inter-
action of both factors.
The analysis outlined above showed increased tremor-related
activity in patients with dopamine-resistant versus dopamine-
responsive tremor in a cerebellar region that included the deep
cerebellar nuclei. As the contribution of dentate nucleus, inter-
posed nucleus and fastigial nucleus to Parkinson’s disease
tremor differs (Muthuraman et al., 2018), we post hoc com-
pared tremor amplitude-related activity between these nuclei
using one-way ANOVA in the dopamine-resistant group.
The deep cerebellar nuclei were defined using the Anatomy
toolbox (based on Diedrichsen et al., 2011); average activity
was calculated using MarsBar (Brett et al., 2002).
Regions of interest
We focused on brain regions consistently involved in
Parkinson’s tremor, i.e. the contralateral motor cortex (MC),
[Brodmann area (BA) 4/6, 3712 mm3] (Helmich et al., 2011),
contralateral ventrolateral thalamus (VLpv, 768 mm3) (Morel
et al., 1997), ipsilateral cerebellum (lobule V/VI, 1416 mm3)
(Helmich et al., 2011), and contralateral internal globus palli-
dus (GPi, 664 mm3) and external globus pallidus (GPe, 2256
mm3), from the Basal Ganglia Human Area Template toolbox
(Prodoehl et al., 2008). Given our previous findings showing
specific effects of dopaminergic medication on tremor-related
activity in the GPi and VLpv (Dirkx et al., 2017), we focused
the Group Medication interaction on these regions. Statistics
were performed at the voxel level, and we corrected for mul-
tiple comparisons using the family-wise error (FWE) correc-
tion. Finally, we explored group differences in tremor-related
activity outside these regions of interest, by performing a
whole brain search with a cluster-forming threshold of
P = 0.001, correcting for multiple comparisons at the whole
brain using a threshold of P5 0.05 FWE corrected (Eklund
et al., 2016). We used the SPM Anatomy Toolbox (Eickhoff
et al., 2005) to locate detected clusters.
Physio-physiological interaction
The univariate analysis revealed several new group-specific
clusters of tremor-related activity. We tested whether these re-
gions showed tremor-specific functional connectivity with cere-
bral regions involved in tremor. For this, we performed a
physio-physiological interaction analysis (PPI) (Friston et al.,
1997) with the seed region’s brain activity (blood-oxygen level-
dependent, BOLD), fluctuations in tremor-amplitude (EMG),
and their interaction (PPI, calculated as the unconvolved
BOLD times unconvolved EMG signal with subsequent
haemodynamic convolution) (Fig. 4). We also included the
usual regressors of no interest (whole brain and lateral ven-
tricle signal). Contrasts specifying the physio-physiological
interaction entered a second level analysis. We used a two-
sample t-test to look for group-specific interaction differences
in any node of the tremor circuitry.
Supplementary analyses
We carried out five supplementary analyses to further specify
our main findings. First, we scrutinized the criteria to define
dopamine-resistant and responsive tremor, given that there is
currently no consensus on this matter. Thus, we added a data-
driven, automated two-step clustering approach based on clin-
ical and electrophysiological tremor parameters to distinguish
between patients with a dopamine-responsive versus a dopa-
mine-resistant tremor (Dirkx et al., 2018). This procedure
confirmed the presence of dopamine-resistant and dopamine-
responsive subtypes in our sample, but the overlap with our
clinically defined subgroups was not complete. Thus, we re-
analysed the functional MRI data using the data-driven
classification.
Second, we explored whether brain regions showing group-
specific tremor-related brain activity (i.e. cerebellum and super-
ior parietal cortex for dopamine-resistant tremor; OP4 for
dopamine-responsive tremor) were functionally connected to
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our previously identified tremor circuit, using seed-based
analyses.
Third, we used dynamic causal modelling (DCM) to repli-
cate our previous finding that dopamine reduces tremor-related
activity by increasing the self-inhibitory connection of the
VLpv, and that this effect is greater in dopamine-responsive
patients (Dirkx et al., 2017). As DCM requires that identical
cerebral nodes are used in each model that enters a model
comparison, we could not use DCM to test whether these
group-specific regions had group-specific influences on the
tremor circuit.
Fourth, given that dopamine inhibits thalamic tremor-related
activity, we calculated the genetic expression of dopamine re-
ceptor D1 (DRD1) and D2 (DRD2) in the VLpv, using post-
mortem data (n = 6) from the Allen Human Brain atlas
(Hawrylycz et al., 2015).
Fifth, we investigated whether differences in cerebellar activ-
ity between groups could be explained by an increased amount
of tremor in the dopamine-resistant group during the levodopa
session. For this, we post hoc compared mean beta values
(extracted from the cerebellar region showing a whole-brain
corrected main effect of Group) for each session separately
using two-sample t-tests. Furthermore, we tested whether
there was a between-session difference in tremor variance
(measured using EMG) by calculating the coefficient of vari-
ation and performing a repeated measures ANOVA. In add-
ition, we repeated our functional MRI analyses after adding
two covariates describing tremor amplitude of the most af-
fected upper extremity and tremor constancy (derived from
the MDS-UPDRS item 17 measured on both scanning days)
to our random-effects analysis. We also investigated whether
usage of beta-blockers influenced cerebellar activity by repeat-
ing the functional MRI analyses while excluding two dopa-
mine-resistant patients who used a beta-blocker with a
possible incomplete wash-out during scanning sessions.
Data availability
The data are not publicly available due to their containing
information that could compromise the privacy of research
participants and written consent for data sharing was not
obtained.
Results
Study population
Of 83 tremulous Parkinson’s disease patients who under-
went a levodopa challenge test, we selected 19 patients with
a relatively dopamine-resistant tremor and 21 with a rela-
tively dopamine-responsive tremor (Table 1). After scan-
ning all 40 patients, we included 14 dopamine-resistant
and 20 dopamine-responsive tremor patients in our ana-
lyses (Table 1 and Fig. 1B–D for clinical characteristics).
We found a significant difference in dopamine response
(Levodopa versus Placebo) between both groups for total
MDS-UPDRS scores and for MDS-UPDRS limb resting
tremor items (most-affected side, amplitude and constancy),
but not MDS-UPDRS non-tremor items (limb bradykinesia
and rigidity). Importantly, both groups showed an overall
response to dopaminergic medication (Table 1) confirming
that the dopamine-resistance of tremor was not a conse-
quence of general failure of levodopa effectiveness, e.g. be-
cause of gastrointestinal malabsorption.
Tremor-related brain activity
During the placebo session (when tremor was most pro-
nounced), patients showed significant tremor-related activ-
ity within the cerebello-thalamo-cortical circuit (Fig. 2 and
Table 2). This replicates previous findings. We did not find
significant tremor-change related activity in the GPi or GPe
(Helmich et al., 2011; Dirkx et al., 2016, 2017). There
were no brain regions showing a Medication  Group
interaction, and there were no main effects of Medication
on tremor-related activity. When testing for differences be-
tween groups (collapsed over medication sessions), we
found that patients with a dopamine-resistant tremor had
significantly more tremor amplitude-related activity than
dopamine-responsive patients in the cerebellum—hereafter
referred to as CBLM2: lobule IV (13%), lobule V (11%),
vermis IX (11%) and deep cerebellar nuclei [nucleus fastigii
(11%), interposed nucleus (4%)]; percentages correspond
to fraction of cluster located within each anatomical
region, ipsilateral to the side of tremor (Fig. 3A). Tremor-
related activity tended to differ between the three deep cere-
bellar nuclei [F(2) = 3.16; P = 0.053], and was highest for
the interposed nucleus (fastigial nucleus versus interposed
nuclei) [t(13) = 2.3; P = 0.04], fastigial nucleus versus den-
tate [t(13) = 2.7; P = 0.02] and interposed versus dentate
nuclei [t(13) = 3.0; P = 0.01] (Fig. 3A). This is in line with
a recent study linking cerebellar tremor oscillations of
Parkinson’s disease to the interposed nucleus
(Muthuraman et al., 2018). Patients with dopamine-resist-
ant tremor also had significantly more tremor change-
related activity in the superior parietal cortex [SPC, area
7P (24%) and 7A (23%)] (Fig. 3) contralateral to the
tremor, as compared to patients with dopamine-responsive
tremor. Conversely, patients with a dopamine-responsive
tremor had significantly more tremor amplitude-related ac-
tivity in the VLpv and somatosensory regions of the par-
ietal cortex [from now referred to as OP4: OP4 (31%),
OP3 (8%), TE3 (10%) and Brodmann area 3b (7%)]
contralateral to the tremor (Fig. 3B).
Physio-physiological interaction
Dopamine-responsive patients had significantly greater
tremor-related functional connectivity between OP4 and
the VLpv than dopamine-resistant patients [voxel coordin-
ates: (16 18 2) mm (x, y, z); T = 3.33, P = 0.024
FWE-corrected]. This fits with our main finding that dopa-
mine-responsive patients show greater tremor-related activ-
ity in both OP4 and VLpv and suggests that these regions
interact with each other during tremor episodes (Fig. 4).
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Conversely, there were no significant interactions for
Resistant4Responsive contrasts.
Supplementary analyses
For details, see the online Supplementary material. First, a
data-driven automated clustering method using subjective
(i.e. MDS-UPDRS) and objective (i.e. accelerometry) meas-
urements of tremor dopamine-responsiveness revealed three
groups: dopamine-responsive, dopamine-resistant and an
intermediate category. Six of 20 patients originally defined
as dopamine-responsive fell into the intermediate category,
and one was classified as dopamine-resistant. Conversely,
only 1 of 14 dopamine-resistant patients was classified as
intermediate. Functional MRI analyses on these new groups
of 13 dopamine-responsive and 14 dopamine-resistant pa-
tients yielded roughly the same results.
Second, the clusters in the somatosensory cortex (i.e.
OP4) and cerebellum (CBLM2), but not in the SPC,
showed significant functional connectivity with all regions
of the tremor circuit (except CBLM25 4MC).
Third, we replicated our previous finding that, across all 34
patients, a model where dopamine influenced tremor-related
activity by acting on the inhibitory self-connection of the
VLpv was more likely than effects of dopamine on any
other possible connection or a ‘null’ model where dopa-
mine did not exert any effect (Dirkx et al., 2017).
Moreover, the probability of this model was significantly
larger in patients with a dopamine-responsive versus dopa-
mine-resistant tremor. This replicates our previous finding
that the modulatory effect of dopamine onto the VLpv is
higher in patients with a relatively dopamine-responsive
tremor (Dirkx et al., 2017).
Fourth, in six post-mortem brains from the Allan Human
Brain Atlas, we found a high genetic expression of the
dopamine D2 receptor (compared to the dopamine D1 re-
ceptor) in the VLpv, but not the motor cortex or cerebel-
lum. This supports our current and past DCM finding that
dopamine inhibits (tremor-related) activity in the VLpv
(Dirkx et al., 2017).
Fifth, activity in CBLM2 was significantly different be-
tween groups for both the placebo and the levodopa ses-
sions separately (Fig. 2), indicating that this result was not
driven by increased amount of tremor in the dopamine-re-
sistant group. Additionally, we ruled out group and ses-
sion-specific differences in the variability of the EMG
regressor (coefficient of variation). Moreover, adding cov-
ariates describing tremor amplitude and constancy for each
individual patient did not alter our functional MRI results.
Figure 2 Similarities in tremor-related activity across both subgroups. Figure displaying tremor amplitude-related activity across both
groups (top) and comparison of mean beta values between groups (bottom). Both subgroups show similar tremor amplitude-related activity in the
cerebello-thalamo-cortical circuit. The bar graphs show the mean beta values (  SEM) and all individual datapoints within each region of interest.
The left side of the figure depicts the left side of the brain (which was always contralateral to the side of the tremor). A threshold of P = 0.001
uncorrected was used for graphical purposes.
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Finally, exclusion of two dopamine-resistant patients with a
possible incomplete beta-blocker washout (due to long half-
life) revealed the same significant CBLM2 cluster indicating
that beta-blocker usage did not influence our results.
Discussion
We investigated the cerebral mechanisms underlying dopa-
mine-resistant versus dopamine-responsive tremor in 34
Parkinson’s disease patients. Informed by earlier work, we
hypothesized that dopamine-resistant tremor is associated
with increased tremor-related activity in non-dopaminergic
areas of the tremor circuity, and more specifically in the
cerebellum. In both groups, tremor was associated with
cerebral activity in a cerebello-thalamo-cortical circuit,
replicating previous findings (Dirkx et al., 2016). There
are three main new findings. First, patients with dopa-
mine-resistant tremor showed increased tremor amplitude-
related activity in the cerebellum (lobules IV/V/IX and
cerebellar nuclei, particularly the interposed nucleus). In
these patients, those non-dopaminergic regions might be
involved in the generation of dopamine-resistant tremor.
Second, patients with dopamine-responsive tremor had
increased tremor amplitude-related activity in the VLpv nu-
cleus of the thalamus, in parietal somatosensory areas
(OP4), as well as increased tremor-related connectivity be-
tween OP4 and VLpv. This suggests that tremor-related
somatosensory afference influences regions involved in
tremor generation, which in turn may affect the dopa-
mine-responsiveness of the tremor. Third, levodopa targets
tremor-related activity in the VLpv of both groups (in line
with Dirkx et al., 2017)—but this effect is greater in dopa-
mine-responsive patients (Supplementary material and
Dirkx et al., 2017). These three findings suggest that dopa-
mine-resistance in Parkinson’s disease tremor may be ex-
plained by increased excitatory cerebellar influences and
reduced somatosensory influences onto the cerebellar thal-
amus (VLpv), making this key thalamic node of the tremor
circuit resistant to dopaminergic inhibition.
The tremor circuitry of
dopamine-responsive versus
dopamine-resistant tremor
This work strongly builds on previous work where we
found tremor amplitude-related activity in a cerebello-tha-
lamo-cortical motor loop of Parkinson’s disease patients
(Helmich et al., 2011; Dirkx et al., 2016, 2017). Here,
we replicate this result and show that this basic tremor
circuit is present in both dopamine-responsive and dopa-
mine-resistant tremor. We also found four brain regions
where tremor-related activity differed between groups. As
these effects were unrelated to levodopa, involvement of
these regions in dopamine-responsive and resistant tremor
Table 2 Clinical characteristics on scan days
MDS-UPDRS evaluated on scan days Resistant tremor (n = 14) Responsive tremor (n = 20) ANOVA (repeated
measures)
Placebo L-DOPA Placebo L-DOPA
Total 40.4 (18.5) 35.9 (19.4) 44.9 (3.3) 32.6 (12.2) F(1,32) = 6.4; P = 0.016
Limb bradykinesia 14.7 (8.1) 11.8 (8.5) 17.2 (5.5) 12.8 (8.7) N.S.
Limb rigidity 4.2 (4.7) 3.8 (3.1) 5.5 (2.6) 4.2 (2.9) N.S.
Limb resting tremor
MA-UE 3.0 (0.7) 3.1 (0.7) 2.6 (0.9) 2.1 (1.3) F(1,32) = 5.12; P = 0.031
MA-LE 1.4 (0.9) 1.3 (1.0) 1.4 (1.2) 0.9 (0.9) N.S.
LA-UE 1.4 (1.1) 1.3 (1.1) 1.2 (1.3) 1.1 (1.3) N.S.
LA-LE 0.9 (0.8) 0.9 (0.9) 1.1 (0.9) 0.7 (0.9) N.S.
Lip 0.2 (0.4) 0.2 (0.4) 0.2 (0.4) 0.2 (0.4) N.S.
Constancy 3.6 (0.7) 3.8 (0.6) 3.1 (1.3) 1.8 (1.4) F(1,32) = 11.8; P = 0.002
Limb postural tremor
MA 1.7 (0.9) 1.4 (1.1) 1.1 (0.7) 0.9 (0.7) N.S.
LA 0.9 (0.7) 0.6 (0.6) 0.7 (0.6) 0.4 (0.6) N.S.
Limb kinetic tremor
MA 1.1 (0.6) 1.1 (0.7) 1.1 (0.6) 0.8 (0.6) N.S.
LA 0.9 (0.7) 0.6 (0.6) 0.8 (0.6) 0.7 (0.7) N.S.
EMG: tremor presence, % and frequency (Hz)
MA-UE 100% (4.2) 93% (4.0) 100% (4.9) 60% (4.6) NA
LA-UE 64% (4.3) 29% (3.9) 65% (4.8) 20% (4.0) NA
MA-LE 14% (4) 0% (NA) 30% (4.8) 10% (4.5) NA
Disease severity of each patient was measured using the MDS-UPDRS part III (maximum score is 132). Limb rigidity is calculated as the sum of MDS-UPDRS item 3 (excluding item
‘Neck’; min–max score 0–16), limb bradykinesia as the sum of items 4–8 (min–max score 0–40). All tremor (sub)items of the UPDRS are displayed (items 15–17; min–max score 0–4
per sub-item). Group comparisons are done using a repeated measures ANOVA. LA = least affected; LE = lower extremity; MA = most affected; N.S. = not significant; N.A. = not
applicable; UE = upper extremity.
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is not explained by (subthreshold) effects of dopamine in
the resistant group. Instead, the differential involvement of
these four regions may reflect altered efferent or afferent
processing of tremor signals, which in turn could influence
the resilience of tremor to dopaminergic intervention, as
elaborated below.
Patients with a dopamine-resistant tremor showed
increased tremor amplitude-related activity in the cerebellar
cortex (lobules IV/V/IX) and in the deep cerebellar nuclei.
This cerebellar cluster is located closely to the cerebellar
region where both groups showed tremor-related activity
in this and earlier studies (Helmich et al., 2011; Dirkx
et al., 2016, 2017). Part of this region (lobules IV/V) has
been associated with ipsilateral limb movement (Kelly and
Strick, 2003; Ramnani, 2006). Lobule IX seems essential
for visual guidance of movement (Glickstein et al., 1994),
although recent functional connectivity studies suggest it
may also be part of a tertiary somatomotor representation
(Yeo et al., 2011). The dentate and interposed nuclei pri-
marily control limb movement via cerebello-thalamo-cor-
tical pathways, whereas the fastigial nucleus is involved
in axial, proximal and ocular motor control (Diedrichsen
and Bastian, 2014; Zhang et al., 2016). The presence of
tremor-related activity within the deep cerebellar nuclei,
and specifically in the interposed nuclei (Fig. 3), is in line
with recent EEG findings showing that the cerebellar source
of Parkinson’s disease tremor is closest to the interposed
nucleus (Muthuraman et al., 2018), and that -synuclein
aggregation in the cerebellar deep nuclei of Parkinson’s dis-
ease patients might be linked to the occurrence of (dopa-
mine-resistant) tremor (Seidel et al., 2017). There are at
least three different mechanisms that could explain the in-
volvement of the cerebellar nuclei in dopamine-resistant
tremor, with different implications for dopaminergic inter-
vention. First, given that the interposed nucleus sends glu-
tamatergic projections to the VLpv (Diedrichsen and
Bastian, 2014), patients with dopamine-resistant tremor
may have increased thalamic excitation. This can explain
why a dopaminergic intervention (which targets the VLpv)
(Dirkx et al., 2017) is insufficient to reduce tremor. In this
case, the enhanced excitatory drive from the cerebellar
nuclei to VLpv may be balanced by higher doses of dopa-
minergic medication. This would fit the theory that tremor
suppression is a threshold phenomenon with respect to the
dose of levodopa required (Obeso et al., 2017). Second,
given that there are multiple oscillators involved in
Parkinson’s disease tremor (Cagnan et al., 2014), increased
cerebellar activity may reflect oscillatory activity in the deep
cerebellar nuclei. In this case, higher doses of dopaminergic
medication would not overcome dopamine resistance, given
that the oscillator in the thalamus is replaced by an oscil-
lator in the deep cerebellar nuclei. This ‘whack-a-mole’
Figure 3 Differences in tremor-related activity across both subgroups. Figure showing where dopamine-resistant (A) and dopamine-
responsive (B) had significantly more tremor amplitude-related activity compared to the other subgroup across both sessions. For the cerebellar
cluster (Resistant4Responsive) the contribution of the three deep cerebellar nuclei is also displayed (only for the dopamine-resistant group).
The bar graphs show the mean beta values (  SEM) and all individual datapoints of the significant clusters (cerebellum and somatosensory areas)
and voxel (VLpv). The left side of the figure depicts the left side of the brain (which was always contralateral to the side of the tremor). A
threshold of P = 0.001 uncorrected was used for graphical purposes.
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effect has been described for essential tremor, where phase
specific deep brain stimulation of the thalamus suppressed
the dominant tremor frequency only to be replaced with a
new oscillation at a lower frequency (Cagnan et al., 2017).
Third, tremor-related activity in the interposed nucleus
(which receives somatosensory afferent input) (Elble et al.,
1984) might represent altered afferent processing of tremor-
related signals in dopamine-resistant tremor.
Patients with dopamine-responsive tremor also showed
increased tremor amplitude-related activity in the VLpv
and a cluster consisting of mostly primary and secondary
somatosensory cortex (i.e. OP4, OP3 and BA3b) in add-
ition to a small portion of auditory cortex (i.e. TE3).
Although the mean beta values displayed in Fig. 2B suggest
that activity in the VLpv was dependent on levodopa (in
line with our current and previous DCM results) (Dirkx
et al., 2017), this did not reach significance, possibly due
to a limited sample size (see limitations below). BA3b, a
portion of the primary somatosensory cortex (Kaas, 2004),
has relatively focal receptive fields, whereas OP4 and OP3
are portions of the human parietal operculum (Eickhoff
et al., 2006) with bilateral receptive fields. Both regions
have already been linked to Parkinson’s rest tremor in pre-
vious EMG-functional MRI and EMG-MEG studies
(Timmermann et al., 2003; Pollok et al., 2009; Helmich
et al., 2011). Here, we add the finding that tremor-related
functional connectivity between VLpv and OP4 is increased
in dopamine-responsive tremor patients. Previous studies
have shown that a significant portion of tremor cells in
the ventral intermediate nucleus of the thalamus (VIM,
which encompasses the VLpv) responds to somatosensory
stimulation (Lenz et al., 1994), and that somatosensory
responses in the macaque’s homologue of the VLpv (i.e.
VPLo) are delayed with respect to cortical responses
(Butler et al., 1992). Accordingly, we interpret the increased
tremor-related thalamo-cortical connectivity observed in
the dopamine-responsive group as an indication that
tremor-related signals from the somatosensory cortex
might drive thalamic tremor cells, rather than the other
way around.
Patients with dopamine-resistant tremor also showed a
cluster of tremor change-related activity in the superior par-
ietal cortex (BA7A and 7P). Previous studies have linked
the posterior parietal cortex to processing afferent tremor
Figure 4 Physio-physiological interaction OP4`VLpv. Illustration of tremor-related functional connectivity (physio-physiological inter-
action) between OP4 and VLpv for dopamine-responsive4 dopamine-resistant patients. (A) Seed region (OP4). (B) Results of the PPI showing
significant tremor-related functional connectivity between OP4 and VLpv for dopamine-responsive patients. A threshold of P = 0.001 uncorrected
was used for graphical purposes. (C) Example from a representative subject showing the regressors that are used for PPI analysis including EMG
tremor amplitude (left), first eigenvariate BOLD response of the OP4 (middle) and the interaction between both regressors (right; calculated using
the deconvolved regressors of the left and middle panels with subsequent haemodynamic convolution).
Mechanisms of dopamine-resistant versus responsive tremor BRAIN 2019: Page 3153 of 3157 | 3153
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/article-abstract/142/10/3144/5567526 by R
adboud U
niversity N
ijm
egen user on 18 M
ay 2020
input (Timmermann et al., 2003; Pollok et al., 2009), but
the cluster found in this study lacks clear connectivity to
any region of the tremor circuitry (Supplementary mater-
ial), questioning its functional relevance in dopamine-resist-
ant tremor.
The role of (altered) afferent
processing in Parkinson’s tremor
The findings of this study suggest that differential tremor-
related activity between groups can be linked to differences
in somatosensory processing, raising the possibility that re-
silience to dopaminergic medication can be (partly) ex-
plained by altered processing of afferent, tremor-related
activity. Previous studies have debated the role of
somatosensory feedback in modulating Parkinson’s disease
tremor. On the one hand, several studies indicate that
tremor amplitude can be reduced or stopped/reset by (i)
surgically removing the dorsal roots (Pollock and Davis,
1930); (ii) fixing joints of the trembling limb by application
of a cast (Burne, 1987); or (iii) electrical stimulation of the
median nerve (Britton et al., 1993). On the other hand,
tremor frequency and phase is not (or only to a small
extent) affected by these or other interventions such as (i)
weighing of the tremulous limb (Deuschl et al., 1996); or
(ii) mechanical displacement at wrist joint (Lee and Stein,
1981). Thus, somatosensory input may have a role in mod-
ulating tremor amplitude, but not the occurrence of tremor
per se. Accordingly, Volkmann et al. (1996) have suggested
that Parkinson’s tremor may be generated via an intrinsic
basal ganglia-thalamo-cortical motor loop, while an extrin-
sic spino-cerebellar-thalamo-cortical feedback loop stabil-
izes the 3–6 Hz tremor oscillations. Increased extrinsic
stabilization of tremor oscillations may explain resilience
of tremor to any intervention, including a dopaminergic
one. The current findings cannot distinguish between affer-
ent and efferent activity, but they suggest to investigate
whether manipulating the effect of an afferent intervention
(such as median nerve stimulation) (Britton et al., 1993) on
tremor is correlated with the dopamine response.
Effects of levodopa onto the tremor
circuitry
This work confirms that levodopa acts on the inhibitory
self-connection of the VLpv, and that this effect is greater
in dopamine-responsive tremor patients (Supplementary
material and Dirkx et al., 2017). This dopaminergic effect
onto a cerebellar receiving nucleus of the thalamus is
physiologically plausible and likely inhibitory. First, the
thalamus, including the VLpv, is known to receive dopa-
minergic projections from the mesencephalon (Brown et al.,
Table 3 Tremor-related activity
Voxel level inference (regions of interest)
Contrast Anatomical
label
Anatomical
location
Hemisphere
(wrt tremor)
Tremor
activity type
MNI
(x y z)
T P (FWE
corr.)
Across all
subjects
(n = 34)
MC BA4 (60%)
BA6 (26%)
Contralateral Tremor amplitude 42 22 50 6.0 50.001
VLpv VLpv (Morel Atlas) Contralateral Tremor amplitude 8 6 8 3.4 0.027
CBLM Lobule V (39%)
Lobule VI (49%)
Ipsilateral Tremor amplitude 18 50 18 3.4 0.023
RESP4RESIST VLpv VLpv (Morel Atlas) Contralateral Tremor amplitude 20 18 4 3.3 0.031
Cluster level inference (whole brain corrected)
Contrast Anatomical
label
Anatomical
location
Hemisphere
(wrt tremor)
Tremor
activity type
Cluster
size (voxels)
Local peak
(MNI x y z)
P (FWE
corr.)
RESIST4RESP CBLM Lobule IV (13%) Ipsilateral Tremor amplitude 224 2 52 20 0.02
Lobule V (11%)
Vermis IX (11%)
Nucleus fastigii (11%)
Interposed nucleus (4%)
SPC BA7P (24%) Contralateral Tremor change 250 16 74 48 0.006
BA7A (23%)
RESP4RESIST Somato-sensory
areas
OP4 (31%) Contralateral Tremor amplitude 570 66 8 4 50.001
OP3 (8%)
TE3 (10%)
BA3b (7%)
Table showing the results of one-sample t-tests across the entire cohort in the placebo session and two-sample t-tests between patients with a dopamine-resistant (RESIST) and
dopamine responsive (RESP) tremor across both sessions. Both statistical methods (at cluster and voxel level) are displayed. For the whole brain method statistical inference at the
cluster level was used (threshold cluster searching P = 0.001 uncorrected). Percentages in parentheses behind each anatomical location correspond to percentage of tremor-related
cluster that overlaps with the specified anatomical cluster. BA = Brodmann area; CBLM = cerebellum; MC = motor cortex; OP = operculum; SPC = superior parietal cortex;
TE = temporal area; wrt = with respect to.
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1979; Sanchez-Gonzalez et al., 2005). Second, the Allen
Human Brain Atlas indicates relatively high genetic expres-
sion of dopamine D2 (and not D1) receptors in the VLpv,
which in the basal ganglia is associated with inhibitory ef-
fects (Albin et al., 1989).
The fact that levodopa induced thalamic inhibition in
both dopamine-responsive and resistant tremor patients
may appear surprising, as the dopamine-resistant group
showed no or little clinical effect of dopamine on
tremor. This raises the possibility that dopamine altered
thalamic processing to an extent that is insufficient (sub-
threshold) to induce clinical effects. The observation that
deep brain stimulation of the VIM, which exerts a more
powerful (suprathreshold) inhibitory effect on local thal-
amic neurons, reduces Parkinson’s disease tremor regard-
less of its dopamine response (Lozano et al., 2002), would
fit this explanation. The fact that dopamine reduces
tremor primarily by targeting the VIM (Dirkx et al.,
2017) also explains why DBS of the subthalamic nucleus
is another effective method of treating both dopamine-re-
sistant and dopamine-responsive tremor. To rule out triv-
ial explanations for a subthreshold effect, both groups
were matched in terms of the dopamine responsiveness
of other (non-tremor) symptoms. Nevertheless, it is pos-
sible that patients with a dopamine-resistant tremor need
higher doses of levodopa to reach a threshold of sufficient
thalamic inhibition. Although we cannot rule this out,
both groups received a substantially higher dose during
this experiment than their own morning dose (dopa-
mine-responsive tremor: 54  9.7%; dopamine-resistant
tremor: 71  7.5%; average  SEM, no group difference).
This makes it unlikely that (dopamine-resistant) patients
were under-dosed.
Effects of other neurotransmitters on
Parkinson’s tremor
The group-specific pattern of tremor-related brain activity
in patients with dopamine-resistant and dopamine-respon-
sive tremor was unaffected by levodopa. This raises the
question whether other neurotransmitter systems may be
responsible for dopamine-resistant tremor. Recent studies
indeed suggest that Parkinson’s tremor may also have a
noradrenergic and/or serotonergic basis, and that this
may (in part) explain dopamine-resistance (Doder et al.,
2003). For instance, data from the Parkinson’s
Progression Markers Initiative (PPMI) cohort show
decreased raphe serotonin transporter availability in
Parkinson’s disease, and a correlation between serotonin
transporter depletion and tremor severity (Qamhawi
et al., 2015; Pasquini et al., 2018). Moreover, in these
studies the raphe/putamen binding ratio of 123I-FP-CIT cor-
related with the clinical dopamine response of tremor. This
suggests that the serotonergic system may play a relatively
larger role in patients with a relatively dopamine-resistant
tremor. There is also evidence for a role of the
noradrenergic system in the generation of Parkinson’s
tremor (Isaias et al., 2011), for example illustrated by the
observation that Parkinson’s tremor increases during cog-
nitive stress (Zach et al., 2017). Accordingly, tremor-dom-
inant Parkinson’s disease patients have less degeneration of
the locus coeruleus (the main source of cerebral noradre-
nalin), and tremor increases after intravenous injection of
adrenalin (Barcroft et al., 1952). Whether or not the nor-
adrenergic system plays a larger role in Parkinson’s disease
patients with a relatively dopamine-resistant tremor re-
mains to be investigated. Future studies may focus on the
exact contribution of (nor)adrenaline and serotonin on the
generation of tremor, to further pave the road for new
treatment strategies.
Interpretational issues
Because of our strict inclusion criteria, we could only in-
clude 14 dopamine-resistant patients for final analyses, rais-
ing the question whether this yielded sufficient power. On
the one hand, we found robust tremor-related activity in
the cerebello-thalamo-cortical circuit replicating previous
studies (Helmich et al., 2011; Dirkx et al., 2016, 2017),
suggesting that we had enough power to detect tremor-
related activity. On the other hand, there was no significant
Medication  Group effect for tremor amplitude-related
activity in the VLpv, suggesting that this study was under-
powered for a univariate interaction effect. However, our
connectivity analyses (which are more sensitive than simple
univariate methods) (Dirkx et al., 2016) were able to show
a significant interaction effect on the VLpv self-connection,
replicating previous results (Dirkx et al., 2017). We inves-
tigated differences in cerebral activity between dopamine-
resistant and dopamine-responsive patients, although it has
yet to be established that there are indeed two phenotypes
or if this rather reflects two ends of a normal spectrum. The
results from our data-driven automated clustering approach
(Supplementary material) support this idea, but it remains
to be confirmed in prospective research.
Patients that were included into our functional MRI
study were carefully selected on the basis of a levodopa
challenge that was not placebo controlled (in a larger
sample of 83 patients). It is well-known that Parkinson’s
disease patients are susceptible to the placebo response
(Quattrone et al., 2018). Indeed, the levodopa effect on
Parkinson’s disease symptoms was larger during the uncon-
trolled levodopa challenge (Table 1) than during the pla-
cebo-controlled MRI measurements (Table 2). Hence, it is
possible that there were more dopamine-resistant patients
than the 19 subjects included in our functional MRI study.
However, the purpose of the present study was not to give
a reliable estimate on the prevalence of dopamine-resistant
patients, but to identify the cerebral differences between
dopamine-responsive and dopamine-resistant patients.
During scanning, we corrected for placebo effects by
using a double-blind design where patients either received
a placebo or levodopa-benserazide (200/50mg). Thus, we
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are confident that functional MRI differences between the
two sessions cannot be explained by a placebo effect.
Conclusion
The findings suggest that interindividual clinical differences
in the dopamine response of Parkinson’s disease rest tremor
can be explained by differences in tremor pathophysiology.
While the cerebello-thalamo-cortical tremor circuit was
involved in both dopamine-responsive and dopamine-resist-
ant groups, patients with dopamine-resistant tremor had
increased tremor-related activity in the cerebellar output
nuclei and reduced cortical somatosensory influences on
the ventrolateral thalamus, which in turn was less sensitive
to dopamine. Together, these findings suggest that afferent
and cerebellar influences on the ventrolateral thalamus de-
termine the susceptibility of the VLpv to dopaminergic
medication. These findings may have therapeutic implica-
tions, suggesting that an alteration of cerebellar reactivity
and/or tremor-related processing may improve the clinical
dopamine response of tremor.
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